21. Drugs for Neuromuscular Disorders and Muscle Spasms Flashcards

1
Q

pathophysiology of myasthenia gravis

A
  • autoimmune disorder where antibodies attach to ACh receptor sites -> obstruct binding of ACh and destroy receptor sites
  • lack of ACh impairs transmission of messages at NMJ -> ineffective muscle contraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

characteristics of myasthenia gravis

A
  • skeletal muscle weakness
  • fatigue and ptosis
  • dysphagia and dysarthria
  • respiratory muscle weakness, paralysis, and arrest
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

characteristics of myasthenic crisis

A
  • severe generalized weakness

- involves diaphragm and intercostal muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

triggers of myasthenic crisis

A
  • inadequate dosing of AChE inhibitors
  • emotional stress, menses, and pregnancy
  • infection, surgery, trauma
  • hypokalemia
  • alcohol intake
  • temperature extremes
  • medication interactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

treatment for myasthenic crisis

A

neostigmine (fast acting AChE inhibitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what causes cholinergic crisis

A
  • usually occurs 30-60 minutes after taking anticholinergic meds -> triggered by OD
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

symptoms of cholinergic crisis

A
SLUD
- salivation
- lacrimation
- urination
- defecation
also includes: 
- severe muscle weakness
- possible respiratory paralysis and arrest
- pallor, sweating, and vertigo
- bradycardia 
- fasciculations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what occurs w/ overdosing and under dosing AChE inhibitors (for myasthenia gravis)

A
  • under dose: myasthenia crisis

- overdose: cholinergic crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

how to tell between myasthenia crisis and cholinergic crisis

A

edrophonium - ultra short acting AChE

  • improves myasthenia crisis
  • worsens cholinergic crisis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

4 types of AChE inhibitors

A
  • edrophonium: ultra short acting (diagnosis)
  • neostigmine: short-acting
  • pyridostigmine: intermediate acting
  • ambenonium: long acting
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA of pyridostigmine

A

promotes transmission of neuromuscular impulses across myoneural junctions by preventing destruction of ACh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

uses of pyridostigmine

A
  • myasthenia gravis
  • neuromuscular blocks
  • nerve gas exposure prophylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

side effects/adverse effects of pyridostigmine

A
  • hypotension
  • bradycardia
  • bronchospasm
  • respiratory distress
  • seizure
  • excessive salivation
  • sweating
  • rash
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how to treat myasthenia gravis if pt doesn’t respond to AChE inhibitors

A
  • prednisone (drug of choice)
  • plasma exchange
  • IV immunoglobulin
  • immunosuppression (azathioprine)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what to monitor w/ AChE inhibitors

A
  • assess for signs and sxs of myasthenic crisis
  • sxs of muscle weakness should be reduced in 2-3 days of drug therapy starting
  • administer doses on time
  • take drug before meals if possible
  • have antidote available for cholinergic crisis (atropine)
  • encourage pt to wear medical identification
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

pathophysiology of MS

A
  • autoimmune disorder
  • attacks myelin sheath of nerve fibers in brain and spinal cord
  • causes lesions (plaques)
17
Q

characteristics of MS

A
  • remissions and exacerbations
  • weakness or paralysis of extremities
  • fatigue
  • muscle spasticity
  • dysarthria, dysphagia, ataxia
  • diplopia, blurred vision, vertigo, tinnitus
18
Q

4 classifications of MS

A
  • relapsing remitting (relapse w/ full recovery and residual deficit)
  • primary progressive (slowly worsening neurologic function w/ relapse or remission)
  • secondary progressive (initial course is relapsing remitting then progression w/ or w/o occasional relapses, minor remissions, and plateaus
  • progressive relapsing (progressive from onset w/ acute relapses w/ or w/o full recovery)
19
Q

first-line treatment for MS

A

immunomodulators (slows disease progression and prevents relapses)

20
Q

what type of drug is beta-interferon

A

immunemodulator

21
Q

MOA of beta-interferon

A

antiviral and immune-regulatory properties are produced by interacting w/ specific receptor sites on cell surfaces

22
Q

use of beta-interferon

A

decrease number and severity of MS attacks; slows progression of disability

23
Q

side effects/adverse effects of beta-interferon

A
  • myelosuppression
  • hepatitis
  • neutropenia
  • myalgia
  • anaphylaxis
  • flulike sxs